Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

How Paralympic athletes are helping science learn more about neuropathic pain

Elite athletes train and compete under a watchful eye. Fans and coaches track and measure every step, roll, or throw. But for athletes with a

September 9, 2024

States Sue TikTok, Claiming It’s Addictive and Harms the Mental Health of Children

More than a dozen states and the District of Columbia have filed lawsuits against TikTok on Tuesday, alleging the popular short-form video app is harming

October 9, 2024

Alzheimer’s and X Chromosomes; Identifying Pediatric MOGAD; Vladimir Lenin’s Death

A large-scale X chromosome-wide association study of Alzheimer’s disease identified SLC9A7 as a novel risk locus. (JAMA Neurology) Investigational fosgonimeton did not meet its primary

September 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.